FiercePharma, by Eric Sagonowsky, Apr 10, 2019 For years, drugmakers and PBMs have tussled over who’s to blame for high drug prices. That didn’t change Tuesday when a congressional committee hauled in executives from insulin makers Sanofi, Eli Lilly and Novo Nordisk as well as from pharmacy benefit managers CVS, Express Scripts and Optum. Going […]
FiercePharma, by Arlene Weintraub, Jan 29, 2019 When Dave Lennon, president of Novartis unit AveXis, said in November that the company’s experimental gene therapy to treat spinal muscular atrophy (SMA) could be cost-effective at a price of $4 million to $5 million, some pricing critics immediately raised red flags. But then the Institute for Clinical […]
We would like to use the opportunity to share with you the link to a new book which has finally been released (fresh from the electronic press!) and to which Anke-Peggy Holtorf has contributed two chapters (“Market Access in Germany” and, together with Nigel Cook, “The Role of Patients in Market Access“). Kockaya G, […]
FiercePharma / by Eric Sagonowsky onMay 3, 2017 On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim. Through the first-of-its-kind contract, if a patient on Repatha has a heart attack or stroke, the drugmaker will provide a full refund. As the […]
10. Aug. 2016, FiercePharma, Tracy Staton Copay discount programsbecome popular among biosimilar manufacturers to boost the adoption of their products. These copay assistence programs can come in form of upfront out-of-pocket financial support (e.g. Sun Pharmaceuticals for their Gleevec-alike imatinib mesylate) or the reduction of upfront cost to the patients (e.g. the cost of the […]
February 25, 2016 | By Tracy Staton in FiercePharma In an article in Science Translational Medicine, researchers from the Massachusetts Institute of Technology, Dana-Farber Cancer Institute and the Broad Institute say patient loans could be designed to link payment to the clinical benefits of their treatment. In a way, they would be pay-for-performance deals–an idea […]